EN-3356
Neoplasms, Prostate
Asana BioSciencesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Neoplasms, Prostate cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Avodart Bay State Clinical Trials, Inc. | Phase 4 | BBB |
gsk5471713 GlaxoSmithKline | Phase 1/2 | CCC |
gsk5458514 GlaxoSmithKline | Phase 1/2 | CCC |
p501-as15 vaccine GlaxoSmithKline | Phase 1 | CC |
P-Psma-101 Car-T Cells Poseida Therapeutics, Inc. | Phase 1 | CC |
Rimiducid Poseida Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
EN-3356 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →